Skip to content

Mortality and causes of death amongst people taking HIV treatment in Senegal examined

AZT/3TC/tenofovir regimen effective first-line therapy in resource-limited settings

Grey nails help predict need to start anti-HIV therapy in Malawians

Darunavir (TMC114) approved for use in treatment-experienced patients in US

Cigarette smoking may undermine benefits of potent antiretroviral therapy

PEPFAR and Global Fund both highly effective, but is the funding sustainable?

Is PEPFAR competing or cooperating in treatment scale-up?

Better than expected 'real world' benefits seen in highly treatment-experienced patients on atazanavir

Fat loss beginning to trigger treatment changes in South African patients